Trial Profile
Evaluation of Ecallantide for Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Ecallantide (Primary)
- Indications Angioedema
- Focus Adverse reactions; Therapeutic Use
- Sponsors Dyax